Articles tagged with Cancer Medication
Happiness has been found to be related to the functioning of key body processes, including lower cortisol levels and healthier cardiovascular systems. Researchers also discovered a Chinese herbal medicine component that can inhibit cancer cell growth.
A low-dose blend of celecoxib and Lipitor significantly reduces invasive and non-invasive colon adenocarcinomas by 95% in laboratory animals. The combination targets different molecular pathways to prevent colon cancer development, suggesting a promising approach for maximizing anti-cancer efficacy while minimizing toxicity.
Researchers developed a test to measure CDK activity, which accurately predicts tumor response to Tarceva. A second study found that increased CDK activity correlates with sensitivity to Taxol, providing preclinical evidence for developing a novel device to measure CDK activity in human tissue.
Despite extensive education, few high-risk women consider taking tamoxifen to prevent breast cancer due to concerns over side effects and low perceived risk. Only a small percentage of eligible women would take the drug after learning about its benefits.
Researchers found that ephrin subtype EphrinB activates the EphB receptor, triggering a chemical pathway that stimulates synaptojanin-1 enzyme, essential for cellular endocytosis. This process is crucial for neurotransmitter regulation and nerve cell function.
Researchers found no detectable levels of SV40 in 69 tumors tested using a highly sensitive assay. The study's protocol aimed to eliminate possible contamination from DNA vectors used in laboratories worldwide.
The American Association for Cancer Research has conferred international awards to world-class scientists, with recipients presenting lectures at the AACR Annual Meeting. The honorees represent leading researchers in basic research, clinical care, and prevention.
Researchers have found a trio of proteins that protect tumor cells from destruction by radiotherapy, and a deeper understanding of their relationship could lead to more effective treatment. Genetic testing could help doctors identify the most effective treatment method for each patient's unique cancer tissue.
The AACR-Minorities in Cancer Research-Jane C. Wright Lectureship recognizes outstanding scientists advancing minority investigators in cancer research. Dr. Wright's pioneering work in clinical cancer chemotherapy and leadership in the field have a lasting impact on cancer research.
Cantley's discovery of phosphoinositide 3-kinase (PI3K) revealed a new lipid produced only when cells are stimulated with growth factors or made cancerous. His work has supported the model that PI3K plays a critical role in many human cancers, and its inhibition is being explored for various diseases.
The AACR Minority Scholar Awards program aims to increase minority participation in cancer research by providing opportunities for young scientists and clinicians. The program's 20th anniversary is being celebrated with a special session and gala, honoring past award recipients and recognizing the contributions of minority researchers.
Researchers found that combining chemotherapy with Herceptin before surgery in early-stage breast cancer patients resulted in a 42% higher tumor reduction and 66.7% pathological complete remission rate compared to chemotherapy alone. The combination also showed less risk of heart damage, leading the clinical trial to be halted early.
Dr. Waldemar Debinski has developed a novel treatment approach for glioblastoma, the most aggressive form of brain cancer, by targeting specific receptors on cancer cells. The therapy combines a form of interleukin-13 with a toxin that kills cancer cells without damaging healthy tissue.
Most cancer survivors can return to work after treatment, but a minority face ongoing problems requiring comprehensive support services. The study found that similar numbers of men and women stop working during treatment, with the lowest rates among those with certain types of cancer.
Researchers at Boston Children's Hospital found that high cholesterol levels accelerate prostate cancer growth by activating a cell-survival pathway. Cholesterol-lowering drugs like simvastatin may inhibit tumor growth by inhibiting this pathway.
Researchers found that vaccinating mice with prostate cancer immediately after hormone therapy triggers a stronger T-cell response against the cancer. The strategy could lead to better vaccine effectiveness in humans, delaying the need for additional treatments or hormone therapy.
Researchers found that a specific viral protein EBNA3C triggers uncontrolled growth of B cells, initiating cancer. The study provides new insights into how Epstein-Barr virus drives cancer and paves the way for developing targeted therapeutics.
Researchers at Temple University have developed a new targeted cancer therapy called ON01910, which inhibits Plk1 activity and shows promise in treating advanced and metastatic cancers. The compound has been shown to block tumor cell invasion, angiogenesis, and induce tumor cell death.
The study found finasteride reduced the incidence of prostate cancer by 24.8% compared to a placebo, potentially saving thousands of lives over ten years. Despite an increase in high-grade tumors, the analysis shows that this benefit outweighs the potential drawbacks.
A plant derivative called parthenolide selectively kills leukemia stem cells while sparing normal cells, offering a promising new therapy for leukemia. This breakthrough research identifies molecular pathways that allow parthenolide to induce cancer cell death.
A recent study reveals that cancer cells can develop resistance to gefitinib by mutating the EGFR gene, altering the drug's binding pocket and rendering it ineffective. This finding could lead to the development of new targeted therapies to treat non-small cell lung cancer.
Scientists found that tumors from six patients with non-small cell lung cancer who initially responded to gefitinib or erlotinib but relapsed carried activating mutations in the EGFR gene. The resistant tumor cells also carried a second mutation in the EGFR gene, which causes resistance to these drugs.
Researchers at Purdue University have created a chip with thousands of tiny vessels on top of a material containing pores to mimic synthetic cell membranes. This innovation aims to develop 'laboratories-on-a-chip' that can screen individual drugs and increase the efficiency of drug discovery.
Researchers at Whitehead Institute discover mTOR/rictor complex, a crucial component in Akt's activation process. This finding holds promise for developing targeted cancer therapies by blocking the complex and preventing tumor growth.
Researchers developed T cells targeting Epstein Barr virus antigens to treat advanced nasopharyngeal carcinoma. Six out of ten patients remained disease-free after treatment, with some experiencing partial remission.
Researchers confirm Vioxx increased cardiovascular risk by nearly doubling events, including heart attacks and strokes, in patients with recurrent colon polyps. The trial was stopped early due to safety concerns.
Tamoxifen has been shown to reduce breast cancer recurrence by up to 50% and lower heart disease risk in women with breast cancer. The study found that current use of tamoxifen was associated with a significantly reduced risk of heart disease, particularly in women who had completed less than two years of therapy.
Researchers at Dana-Farber Cancer Institute have developed a new hybrid targeted therapy, AMN107, which kills CML cells more effectively than Gleevec and triggers longer remissions in mice. The study's findings suggest that AMN107 may be an effective treatment option for patients with Gleevec-resistant disease.
A new leukemia drug treatment has shown promise for MDS patients with 5q minus syndrome, becoming transfusion independent in 91% of cases. The defective chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.
The American Association for Cancer Research recognizes Melissa J. Parsons and G. Ruth Thomas as the first award recipients in 2005, honoring their meritorious scientific papers on cell death in oncogenesis. The AACR aims to accelerate cancer prevention and cure through research, education, and advocacy.
A new radioactive antibody treatment called Bexxar has shown promising results in a study, rivaling traditional chemotherapy regimens for follicular lymphoma. The treatment achieved a 95% response rate and 75% complete remission in patients with advanced-stage disease.
Researchers have identified a possible strategy for treating acute viral infections by blocking cellular signaling pathways that viruses depend on for reproduction. The approach, using an experimental cancer drug called CI-1033, has shown promising results in laboratory samples and lab mice infected with viruses similar to smallpox.
A randomized, placebo-controlled trial showed etanercept was ineffective in preventing disease flares for patients with Wegener's granulomatosis. The study found that most patients experienced disease remissions at a high cost due to treatment-associated adverse effects.
A study published in Archives of Internal Medicine found that communication between primary-care physicians and patients can reduce medication-related problems. The researchers discovered that 25% of patients experienced adverse drug events, many of which were preventable, due to a lack of reporting or inadequate doctor response.
A new study published in PLOS Medicine found that patients with KRAS mutations do not respond to targeted therapy drugs erlotinib and gefitinib. Analyzing tumors for EGF receptor and KRAS mutations may be crucial to predicting treatment effectiveness.
Researchers have discovered a new leukemia drug that can overcome all forms of Gleevec resistance, a significant breakthrough for patients with advanced CML. The drug, ON012380, blocks a different site in the BCR-ABL protein and induces cell death in all known Gleevec-resistant mutants.
Researchers at Memorial Sloan-Kettering Cancer Center have identified a new oncogene called Pokemon, which is essential for cancer cell growth and transformation. The discovery opens up new avenues for targeted therapy, with a focus on blocking the protein's function to prevent cancer progression.
Researchers are evaluating the effectiveness of BAY43-9006 alone and paired with gemcitabine in a phase II clinical trial for metastatic pancreatic carcinoma. The trial aims to add much-needed treatment options for this aggressive cancer, which affects approximately 27,000 deaths annually in the US.
A new study by Brown University researchers has discovered a chemical modification that activates the STAT3 protein, which is important for embryonic growth and development. This continuous activation causes breast and prostate cells to develop and move through the body, leading to cancer. The research team found that acetylation, anot...
A study of 69 patients with rectal tumors found that carefree individuals took longer to recognize cancer symptoms due to low anxiety sensitivity. They also reported better overall health despite being seriously ill. The research suggests a different approach is needed to encourage these individuals to seek medical attention.
The American Association for Cancer Research (AACR) has recognized and supported 17 women in cancer research this year, providing them with scholarships to attend conferences. The awardees are from various backgrounds, including graduate students, medical students, and postdoctoral fellows.
The American Association for Cancer Research (AACR) has awarded scholarships to minority researchers, aiming to increase diversity in the field of cancer research. The recipients, all from underrepresented groups, will receive funding to attend AACR Special Conferences and further their careers.
Researchers found that timing is crucial in combining antiangiogenesis and radiation therapy, with a synergistic effect observed when radiation was administered 4-6 days after initiation of DC101 therapy. This approach improved oxygen delivery to the tumor, reducing hypoxia and increasing sensitivity to radiation.
Researchers found that blocking CDK2 activity may control deadly skin cancer without harming normal cells. The study's findings suggest a therapeutic window for a drug that suppresses melanoma growth by shutting down CDK2 activity, potentially leading to a new treatment option.
A Northwestern University study reveals potentially fatal blood clots in up to 20% of cancer patients treated with thalidomide. The drug's exclusive off-label use hinders information sharing about side effects.
Researchers found that Paxceed increased protein travel down spinal axons and improved microtubule density in tau transgenic mice. The drug also reduced motor impairment in the mice.
A newly discovered compound, SP-4-84, has shown potential to enhance cancer treatments by increasing the effectiveness of chemotherapy drugs while reducing side effects. The compound works by inhibiting cancer cells' ability to survive chemotherapeutic treatment, allowing for lower drug dosages and fewer side effects.
The NIH has suspended the use of celecoxib, a COX-2 inhibitor, in its large-scale cancer prevention trial after finding a two-fold increased risk of cardiovascular toxicities. The decision was made following a September 2004 report that highlighted concerns over the safety of rofecoxib, another COX-2 inhibitor.
Researchers at Johns Hopkins Medicine have identified a second source of phosphate in cells, inositol pyrophosphate (IP7), which modifies proteins without ATP's help. IP7's role in regulating brain chemicals and protein synthesis suggests new potential treatments for neurodegenerative diseases.
A team of Cardiff University researchers has secured a £15 million grant to explore DNA damage and disease. The group aims to unravel the complexities of how cells maintain their chromosomes, ultimately establishing cancer risks for individuals and designing new anti-cancer drugs.
Recent research analysis finds no significant link between oral contraceptive use and cardiovascular disease in postmenopausal women. The NHLBI emphasizes the importance of randomized controlled trials for establishing scientific evidence, citing biases and errors in exploratory analyses.
A recent study by UT Southwestern Medical Center found that one-third of long-term disease-free breast cancer patients have circulating tumor cells (CTCs), which are often associated with a higher risk of recurrence. However, the presence of CTCs in these patients after 20 years post-mastectomy is notable due to their low risk of recur...
A study of 129 women with high breast cancer risk found that personal history and physician advice influenced decision-making, while perception of risk and lack of information also played a role. Women were more likely to take tamoxifen if they had an abnormal biopsy or received a doctor's recommendation.
A study found that cancer patients receiving long-term bisphosphonate therapy were at risk of developing jawbone necrosis, a condition that can lead to bone death and require surgery. The condition is often associated with tooth extractions or other major dental work while on the drugs.
Researchers at Scripps Institution of Oceanography have cloned a gene from the marine invertebrate Bugula neritina, which may prove key in developing new cancer drugs. The cloned gene, bryA, is thought to be involved in the production of bryostatin, a family of chemical compounds with potential as anticancer pharmaceuticals.
The phosphatidylinositol 3 kinase (PI3K) pathway is crucial in breast cancer development, with aberrant levels and mutations affecting critical growth factor receptors. Researchers believe targeting central nodes in this pathway can effectively treat the disease.
Researchers found that thiazolidinedione (TZD) class of anti-diabetic therapies can kill multiple myeloma cells by binding to PPAR-gamma protein, showing potential as a new cancer therapy. The effectiveness of TZD drugs was enhanced when combined with Vitamin A-like compounds.
The ATAC study's 5-year follow-up results show anastrozole increased disease-free survival and reduced cancer recurrence, with fewer side effects compared to tamoxifen. Anastrozole is now considered the preferred initial adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer.
Researchers found that breast cancer patients who lose tau protein expression are twice as likely to have a good response to Taxol treatment. The discovery suggests that tumor tissue could be screened to predict which patients will respond to the chemotherapy, leading to improved treatment outcomes.
Scientists have determined how a specific protein blocks DNA replication, providing a key to designing targeted cancer therapies. By understanding the structure of this protein, researchers may also develop new forms of antibiotics.